The Oxford-AstraZeneca Covid vaccine is a viral vector vaccine that was created using the modified chimpanzee adenovirus. It is marketed as Covishield in India and Vaxzevria in Europe.
For the first time, the multinational pharmaceutical company AstraZeneca has formally admitted that the COVID-19 vaccine it sells under the trade names Covishield and Vaxzevria may cause an uncommonly serious health complication. According to The Telegraph, the vaccine’s manufacturer claimed in court filings that there was a chance the shot may occasionally cause thrombosis with thrombocytopenia syndrome (TTS), a condition that causes blood clots and a low platelet count. The company is presently dealing with a class action lawsuit in the UK due to claims that AstraZeneca’s vaccine resulted in fatalities and serious injuries.
The University of Oxford and AstraZeneca worked together to create the vaccine. Under a license from AstraZeneca, the Serum Institute of India (SII) produces Covishield in India. In India, SII has made this vaccination widely available. On the FAQ section of their website, SII, however, has mentioned possible side effects of Covishield. These vary from extremely frequent adverse effects, such as exhaustion and nausea, to extremely uncommon ones, such as significant blood clotting combined with low platelet count, which affect less than one in every 100,000 vaccinated people.
What exactly has AstraZeneca said?
In court records pertaining to a lawsuit filed against the business in the UK, AstraZeneca discussed TTS. The multinational pharmaceutical company is facing legal action about health claims pertaining to a vaccine it co-developed with the University of Oxford during the 2020 Covid-19 pandemic. A case was filed last year by Jamie Scott, a father of two, who was left with a permanent brain injury after receiving the vaccine in April 2021. He developed a blood clot and a bleed on the brain that have prevented him from working, according to a recent report from the UK-based media outlet The Telegraph.
“Fifty-one cases have been lodged in the High Court (in the UK), with victims and grieving relatives seeking damages estimated to be worth up to £100 million,” the paper stated overall.
In February court filings, AstraZeneca refuted the claim that “TTS is caused by the vaccine at a generic level.” Nonetheless, it acknowledged that in “very rare cases,” the vaccine could result in TTS.
What is TTS?
A rare but dangerous illness known as thrombosis with thrombocytopenia syndrome (TTS) is characterized by low platelet counts (thrombocytopenia) and blood clot formation (thrombosis). The symptoms of TTS usually include excruciating headaches, stomach pain, leg swelling, dyspnea, and neurological impairments. Blood tests to measure platelet counts and imaging examinations to find blood clots are part of the diagnosis process. A multidisciplinary strategy is used to treat TTS, which includes supportive care, anticoagulant treatment to stop more clotting, and hospitalization. To control immune-mediated responses and stabilize platelet counts, further treatments include plasma exchange and intravenous immunoglobulin (IVIG).
TTS patients are continuously watched by medical professionals because there is a risk of serious complications, such as organ damage and death. For those suffering from this uncommon but serious illness, prompt identification and treatment are crucial to improve their prognosis.
How head and neck cancers are caused by Covishield, according to an expert
TTS was reported as a novel adverse event following immunization in a report released by the World Health Organization (WHO) in 2023 for those who received COVID-19 non-replicant adenovirus vector-based vaccinations. This is a reference to the COVID-19 Ad26.COV2-S vaccination from Johnson & Johnson (J&J) and the COVID-19 ChAdOx-1 vaccine from AstraZeneca.
“TTS is a dangerous adverse occurrence that can be fatal. The purpose of WHO’s interim emergency guidance, which was released in 2023, was to “raise awareness about TTS in the context of COVID-19 vaccination and assist healthcare providers in the assessment and management of potential TTS cases.”
People Ask For
Which type of vaccine is Covishield?
The vaccine Covishield is based on an adenovirus vector, while Covaxin was created using a conventional vaccine formulation technique using adjuvanted inactivated viral particles. The adjuvants, mechanism of action, and composition of each vaccination affect its usefulness or efficiency.
Is Covishield the same as AstraZeneca?
The AstraZeneca vaccine is a viral vector vaccine intended to provide protection against the SARS-CoV-2 virus, which is the causal agent of Covid-19. It is also referred to as AZD1222 or Covishield in India.
Who is the owner of Covishield?
The COVID-19 Vaccine AstraZeneca (made by AstraZeneca) and COVISHIELDTM (produced by Serum Institute of India Pvt Ltd) are both ChAdOx1 nCoV-19 Corona Virus Vaccines (Recombinant).
Also, visit…
HPBOSE Himachal Pradesh Board 12th Result 2024: Results Out
Drastic Physique Transformation Ranbir Kapoor For Ramayana: Shared by Trainer